A New Alzheimer’s Blood Test Is Here: What It Can—and Can’t—Tell You
If you saw the headlines this week announcing a new blood test for Alzheimer’s disease, you may have had one of two reactions:
“This is incredible. Why aren’t we testing everyone?”
or
“Absolutely not. I forget why I walked into the kitchen at least twice a day.”
Both reactions are understandable.
But the real story is more interesting — and a little more complicated — than “Alzheimer’s can now be diagnosed with a blood test.”
It can’t. At least not quite like that.
What has changed is important, though. On August 24, 2026, the FDA cleared a new blood test called Elecsys pTau217 from Roche and Eli Lilly. It can help doctors determine whether a person with memory or thinking problems has the type of abnormal brain changes associated with Alzheimer’s disease.
And unlike the expensive brain scans and spinal taps that have traditionally been used to look for those changes, this one starts with something considerably less dramatic:
A regular blood draw.
That’s a very big deal.
First: What Is This Test Actually Looking For?
To understand the test, we need about 45 seconds of Alzheimer’s biology. I promise not to turn this into medical school.
Two proteins are particularly important in Alzheimer’s disease: amyloid and tau.
Amyloid can build up between brain cells and form plaques. Tau, which normally helps support the internal structure of nerve cells, can become abnormal and form tangles inside them.
These changes can begin years before dementia becomes severe.
The new test measures a form of tau in the blood called phosphorylated tau 217, usually shortened to pTau217.
Researchers have found that when Alzheimer’s-related amyloid changes are occurring in the brain, pTau217 in the blood often rises as well.
So the test isn’t opening a tiny window into your skull and counting amyloid plaques.
It’s measuring a blood biomarker that gives doctors information about whether that Alzheimer’s-related brain pathology is likely to be present.
That distinction matters.
Does a Positive Test Mean You Have Alzheimer’s?
No.
And this may be the most important sentence in this entire article.
A positive pTau217 blood test does not, by itself, diagnose Alzheimer’s disease.
The FDA-cleared Roche test produces results categorized as positive, negative, or intermediate. Those results are meant to be interpreted along with the person’s symptoms, medical history, cognitive evaluation, physical exam, medications, laboratory studies, imaging when appropriate, and other clinical information.
In other words, your doctor still has to doctor.
A positive result suggests that amyloid pathology associated with Alzheimer’s is likely present.
A negative result makes that pathology less likely.
An intermediate result essentially means, “We need more information.”
Medicine does love an answer that requires another appointment.
Who Is This New Test For?
This particular test is cleared for people 55 and older who already have signs, symptoms, or complaints of cognitive decline.
That last part is important.
This is not currently intended as a routine screening test for every healthy 60-, 70-, or 80-year-old who feels perfectly fine.
It isn’t the cognitive equivalent of checking your cholesterol.
If you occasionally misplace your glasses and eventually discover them on top of your head, you do not need to sprint to the lab.
On the other hand, changes such as these deserve medical evaluation:
● Repeating the same questions or stories without realizing it
● Getting lost in familiar places
● Increasing difficulty managing medications or finances
● Trouble following familiar recipes or completing routine tasks
● Noticeable changes in judgment or problem solving
● Difficulty finding words that is clearly progressing
● Memory problems that family members notice and that interfere with everyday life
The key isn’t one forgotten name or misplaced set of keys.
It’s a change from your normal baseline, especially one that is progressing or interfering with daily function.
Wait — Haven’t We Already Had Alzheimer’s Blood Tests?
Yes.
This is where some of the news coverage gets confusing.
The FDA cleared the first blood test used to aid in diagnosing Alzheimer’s disease in May 2025. That test, Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, measures both pTau217 and beta-amyloid and calculates a ratio.
Other blood-based biomarker tests have followed.
Just days before the Roche announcement, the FDA also cleared PrecivityAD2, another Alzheimer’s blood test, for adults age 40 and older who have signs or symptoms of cognitive impairment.
So what’s new about the Roche test?
Elecsys pTau217 is the first FDA-cleared test that uses pTau217 as a single biomarker and is designed to help clinicians both rule in and rule out amyloid pathology using the same validated cutoffs in primary and specialty care.
That’s less catchy than “NEW ALZHEIMER’S BLOOD TEST!”
But it’s considerably more accurate.
And the bigger story is that Alzheimer’s blood biomarkers are moving out of the research world and toward ordinary clinical medicine.
Why Is a Blood Test Such a Big Improvement?
Until recently, if a doctor needed biological confirmation of Alzheimer’s-related amyloid in the brain, the main options included:
An amyloid PET scan.
This is specialized brain imaging that can show amyloid deposits. It is useful, but it isn’t available everywhere, can be expensive, takes time, and involves a radioactive tracer.
Cerebrospinal fluid testing.
This requires collecting spinal fluid through a lumbar puncture — otherwise known as the test that causes many patients to suddenly become very interested in Option B.
A blood draw is far simpler.
It also has the potential to make good diagnostic testing available to people who don’t live near major memory centers or academic medical centers.
Roche says its test can run on thousands of laboratory analyzers already in use across the United States, and both Labcorp and Quest Diagnostics plan to offer it.
That could eventually make a sophisticated Alzheimer’s biomarker test feel much more like ordering any other specialized blood test.
Why Getting the Diagnosis Right Matters More Now Than It Used To
There was a time when families understandably asked:
Why put someone through an extensive Alzheimer’s workup if there isn’t much we can do about it?
That question is changing.
We now have treatments for early Alzheimer’s disease that can slow disease progression in selected patients. These medications are not appropriate for everyone, they have meaningful risks and monitoring requirements, and they are certainly not cures.
But deciding whether someone might benefit from one of these treatments requires knowing whether Alzheimer’s pathology is actually present.
There are also other very practical reasons to get the diagnosis right.
Not every memory problem is Alzheimer’s.
Cognitive changes can be caused or worsened by things including:
● Medication side effects
● Depression
● Sleep apnea
● Thyroid disease
● Vitamin B12 deficiency
● Alcohol use
● Infection or acute illness
● Hearing impairment
● Vascular disease
● Other types of dementia
I would hate to see someone hear “There’s an Alzheimer’s blood test now,” get a biomarker checked without a proper clinical evaluation, and assume the answer explains everything.
The blood test is another piece of the puzzle.
It is not the entire puzzle.
This Test Is Not the Same as a Genetic Test
Another point worth clearing up: pTau217 testing is not genetic testing.
It isn’t looking for an APOE gene or telling you whether you inherited a risk for developing Alzheimer’s someday.
It’s looking for a biological marker associated with processes happening in the body now.
That’s an important difference, particularly for people who have a parent with Alzheimer’s and are wondering whether they should have the test simply because they are worried about their own future risk.
For someone with no cognitive symptoms, this newly cleared Roche test isn’t intended to answer that question.
What Happens If the Test Is Positive?
This is where I would encourage families not to treat a lab result as a diagnosis delivered through a patient portal.
Please don’t open MyChart at 10:47 p.m., see the word “positive,” Google until 2 a.m., and mentally plan the next ten years of your life before speaking with a clinician.
A positive result needs context.
Your doctor may review:
● What cognitive changes are actually occurring
● When they began and how quickly they’re progressing
● Whether someone close to you has noticed changes
● Your medications
● Other medical conditions
● Cognitive screening or neuropsychological testing
● Bloodwork for other causes of cognitive impairment
● Brain imaging
● Whether further biomarker confirmation is needed
● Whether referral to neurology, geriatrics, or a memory clinic is appropriate
The answer to “Is this Alzheimer’s?” should come from the full clinical picture — not one number.
What About a Negative Result?
A negative Alzheimer’s biomarker result can be extremely useful too.
If amyloid pathology is unlikely, the question becomes:
Then what is causing the cognitive problem?
That’s not a dead end.
That’s valuable information.
It can redirect the evaluation toward vascular disease, another type of dementia, medications, sleep problems, depression, metabolic problems, nutritional deficiencies, or other causes.
Sometimes ruling something out is just as important as ruling it in.
And an “Intermediate” Result?
Welcome to the glamorous world of medical testing.
Not every human being sorts neatly into Yes and No.
An intermediate result may mean that more evaluation is needed, potentially including additional biomarker testing, imaging, or specialist assessment.
It doesn’t mean “probably Alzheimer’s.”
It means the blood test couldn’t answer the question confidently enough on its own.
Can the Test Be Wrong?
Yes.
Every medical test can produce false-positive and false-negative results.
A false positive could make someone believe Alzheimer’s pathology is present when it isn’t.
A false negative could falsely reassure someone whose symptoms actually are related to Alzheimer’s disease.
That is one reason professional guidance around these blood biomarkers emphasizes using appropriately validated tests in people who actually have objective cognitive impairment and interpreting them as part of a full diagnostic evaluation.
The Alzheimer’s Association has already developed clinical guidance for using blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease.
This isn’t intended to become a do-it-yourself diagnosis.
Should You Ask Your Doctor for the Test?
If you or someone you love is experiencing new, persistent, or worsening cognitive changes, yes — I think it is reasonable to ask about it.
But I’d phrase the question this way:
“Would an Alzheimer’s blood biomarker test be useful as part of my evaluation?”
That’s a much better question than:
“Can you order me the Alzheimer’s test?”
Because the goal isn’t to collect another lab value.
The goal is to figure out why something has changed.
Depending on the situation, your primary care provider may be able to begin that workup or may refer you to a neurologist, geriatrician, or memory specialist.
Questions I Would Ask Before Having the Test
If a clinician recommends an Alzheimer’s blood biomarker test, these are reasonable questions:
Which test are you ordering?
There is now more than one Alzheimer’s blood biomarker test available.
What exactly will this result tell us?
What won’t it tell us?
If it is positive, what happens next?
If it’s negative, what causes will we investigate instead?
Would I still need a PET scan, spinal-fluid testing, MRI, or cognitive testing?
Will insurance cover it, and what will it cost me?
Would the result change my treatment or care plan?
That last question is one of my favorites for almost any medical test.
A test should ideally help us make a decision.
One More Thing Families Should Know
A diagnosis of cognitive impairment rarely affects only the person sitting on the exam table.
Suddenly there are appointments. Medication decisions. Driving questions. Financial decisions. Specialists saying slightly different things. Adult children trying to compare notes in a family text thread that now has 73 unread messages.
And the person undergoing the evaluation is being asked to absorb complex information at exactly the moment we are concerned about their ability to process and remember it.
This is one of those situations where bringing another set of ears to appointments matters.
Write questions down beforehand.
Take notes.
Ask the clinician to explain what a test result means in plain English.
Ask what happens next.
And if the medical system becomes difficult to coordinate, that’s exactly the kind of situation where a patient advocate can help connect the dots between providers, test results, medications, family concerns, and the patient’s actual goals.
The Bottom Line
The new Alzheimer’s blood tests are genuinely exciting.
They have the potential to make accurate evaluation faster, easier, less invasive, and available to far more people than relying primarily on specialized brain scans and lumbar punctures.
But they aren’t crystal balls.
They can’t tell a healthy person exactly whether or when they will develop dementia.
They aren’t a replacement for a careful medical evaluation.
And a positive blood result should never be treated as a diagnosis in isolation.
What they can do is give clinicians another powerful piece of information when someone is already experiencing cognitive changes.
And that may help families get to the right answer sooner.
When you’re worried about someone’s memory, sooner matters.
Not because every forgotten word is Alzheimer’s.
But because figuring out what is actually happening is the first step toward doing something useful about it.
